Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R.
Michlmayr A, et al.
Br J Cancer. 2010 Oct 12;103(8):1201-8. doi: 10.1038/sj.bjc.6605909. Epub 2010 Sep 28.
Br J Cancer. 2010.
PMID: 20877360
Free PMC article.
Clinical Trial.